Carvedilol Tablet, Film Coated
Product Images NDC 0904-7306

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 0904-7306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This appears to be a description showing a comparison between Placebo and Carvedilol at different time points, such as 3, 6, 9, 12, 15, 18, and 21 months. The statistical significance is indicated with a p-value of 0.0014.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This appears to be a list of criteria or variables related to a study or analysis involving men and women with different characteristics such as age, race, health conditions, and physiological parameters like heart rate and blood pressure. The text also includes terms like Spironolactione, hazard ratio, and statistical symbols. These variables may be used to analyze and compare different groups of patients based on the outlined criteria.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This text shows survival analysis results for the CAPRICORN study comparing placebo and carvedilol in an intent-to-treat analysis. It indicates a statistically significant difference in mortality between the two groups, with a p-value of 0.03. The graph depicts the survival rates over a 24-month period.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This description provides insights on the effects of various subgroups on mortality in the CAPRICORN study. It includes details such as age criteria, gender differences, use of diuretics, presence of angina, hypertension, diabetes, heart rate, thrombolytic therapy, blood pressure levels, and PTCA for myocardial infarction. The text appears to present data on Hazard Ratios for different factors in relation to mortality outcomes.*
FDA Label Image

3.125mg Carton Label (Image 01)

3.125mg Carton Label (Image 01)
FDA Label Image

25mg Carton Label (Image 02)

25mg Carton Label (Image 02)
This text is a description of Carvedilol Tablets, USP in a package containing 100 tablets. It mentions storage instructions at 20 to 25°C, the importance of using safety closures when dispensing, and that the product meets USP Dissolution Test 2. The packaging emphasizes that it is child-resistant and intended for institutional use only. The drug is associated with NEC's Shear 155 Clancy Pharmaceuticals and is packaged and distributed by ALK Pharmaceuticals.*
FDA Label Image
Logo (Logo)
FDA Label Image

Logo1 (Logo1)

Logo1 (Logo1)
FDA Label Image

Carvedilol-chemical-structure (Structure)

Carvedilol-chemical-structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.